Skip to content

A pilot study on the efficacy and safety of the use of a synbiotic formula (SCV09) in people with Mild Cognitive Impairment (MCI)

A pilot study on the efficacy and safety of the use of a synbiotic formula (SCV09) in people with Mild Cognitive Impairment (MCI)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109058
Enrollment
Unknown
Registered
2025-09-11
Start date
2025-09-24
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impairment

Interventions

MCI group:SCV09

Sponsors

The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Chinese individuals aged between 60-85; 2.Mild cognitive impairment as determined by a Clinical Dementia Rating (CDR) = 0.5; 3.Hamilton Depression Rating Scale (HAM-D) >= 8, and that the mood symptoms occurred after MCI onset; 4.Having a family member or caregiver who could supervise the subject in taking the study products, collecting stool samples and attending the follow-up; 5.Able to provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Diagnosed with dementia, or already receiving drugs for dementia, such as cholinesterase inhibitors, memantine, and amyloid-targeting monoclonal antibodies; 2. Concomitant Parkinson’s disease and other neurodegenerative conditions affecting activities of daily living 3. Psychotic, suicidal, or treatment-resistant; 4. History of stroke; 5. History of severe organ failure (including decompensated cirrhosis), renal failure on ; dialysis, suffering from human immunodeficiency virus infection; 6. Pre-existing gastrointestinal diseases that significantly confound gut microbiota (eg, inflammatory bowel disease) 7. Confirmed active malignancy; 8. Known operations involving small intestines and large intestines; or history of appendectomy, hysterectomy, and cholecystectomy in the last 6 months; 9. Use of antipsychotics, antidepressants or sedatives, unless on a stable dose in the last 3 months; 10. Inability to receive oral fluids; 11. Use of antibiotics, probiotics or prebiotics in the last 2 weeks; 12. Intolerance to probiotics or lactose leading to a severe allergic reaction.

Design outcomes

Primary

MeasureTime frame
Proportion of subjects with improvement in condition;

Secondary

MeasureTime frame
Self-report improvement in condition;Changes in the Clinical Dementia Rating;Changes in Hong Kong version of Montreal Cognitive Assessment (HK-MoCA) score;Changes in the Chinese version of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) score;Changes in Hamilton Depression Rating Scale (HAM-D);Changes in Hamilton Anxiety Rating Scale (HAM-A);Changes in the Neuropsychiatric Inventory (NPI) score;Changes in the gut microbiota composition and functions;Adverse event rates;

Countries

China

Contacts

Public ContactAllen Ting Chun LEE

The Chinese University of Hong Kong

allenlee@cuhk.edu.hk+852 2607 6031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026